Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis

Abstract Background ABP 710 is being developed as a biosimilar to infliximab reference product (RP). Analytical similarity and pharmacokinetic equivalence between the two have been previously demonstrated. Here we report results from a comparative clinical study that evaluated the efficacy and safet...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Mark C. Genovese, Juan Sanchez-Burson, MyungShin Oh, Eva Balazs, Jeffrey Neal, Andrea Everding, Tomas Hala, Rafal Wojciechowski, Gary Fanjiang, Stanley Cohen
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	BMC 2020-03-01
Saila:	Arthritis Research & Therapy
Gaiak:	ABP 710 Infliximab Biosimilar Rheumatoid arthritis
Sarrera elektronikoa:	http://link.springer.com/article/10.1186/s13075-020-2142-1
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!